Relief in sight for Migraine sufferers?

Posted on October 7, 2016
Archive : October 2016
Category : News

Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine!

Amgen (NASDAQ:AMGN) today announced positive top-line results from the global Phase 2 study evaluating the efficacy and safety of erenumab (AMG 334) in chronic migraine prevention. 

The study met its primary endpoint of change in monthly migraine days. The reduction in migraine days was statistically significant for both the 70 mg and 140 mg doses.

Migraine is the sixth leading cause of disability worldwide. These positive results are exciting because they add to the growing body of evidence supporting erenumab for the prevention of migraine.

Patients enrolled in this study were experiencing approximately 18 migraine days per month. Patients were randomized to receive either placebo, or one of two erenumab doses — 70 mg or 140 mg — subcutaneously, once monthly. Patients experienced a 6.6-day reduction in monthly migraine days in each of the erenumab treatment arms as compared to a 4.2-day reduction in the placebo arm, a statistically significant reduction in each erenumab treatment arm.

The safety profile of erenumab was similar to placebo across both treatment arms. No adverse event was reported in greater than five percent of patients treated with erenumab; the most common adverse events were injection site pain, upper respiratory tract infection and nausea.


Click here to read the full article.